(Q43038324)

12 November 2017

title

The IL-28B genotype predicts which slow-responding hepatitis C-infected patients will benefit from treatment extension (English)

1 reference

12 November 2017

Brian L Pearlman

1

1 reference

12 November 2017

Carole Ehleben

series ordinal

2

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

The American Journal of Gastroenterology

12 November 2017

published in

1 reference

12 November 2017

volume

106

1 reference

12 November 2017

issue

7

1 reference

12 November 2017

page(s)

1370-1371

1 reference

https://scigraph.springernature.com/pub.10.1038/ajg.2011.149

12 November 2017

exact match

0 references

cites work

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.149

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.149

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.149

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.149

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.149

1 reference

Dimensions Publication ID

12 November 2017

1003186329

0 references

1 reference